Late clinical-stage biopharmaceutical company Vistagen has announced that the European Patent Office (EPO) plans to grant a patent for its PH80 nasal spray, which is designed to treat migraines. The patent claims include treatment administered at the onset of migraine symptoms and treatment of migraines associated with traumatic brain injury. PH80 nasal spray initiates neural impulses in the olfactory bulb transmitted by pathways that rapidly affect the function of multiple structures in the brain, including those linked to the pathology of migraine. Once granted, the patent will not expire until at least 2040. Migraine affects more than one billion individuals each year across the world and is one of the most common neurological disorders.
Keywords: Vistagen, European Patent Office (EPO), PH80 nasal spray, migraines, neural impulses.
Vistagen's PH80 nasal spray for migraines is set to receive a patent from EPO, which will be valid till 2040. This new product can potentially transform treatments for individuals living with anxiety, depression and other central nervous system disorders. In addition to treating migraines at their onset and those associated with traumatic brain injuries, it also provides an excellent safety profile in all clinical trials conducted so far. With over one billion people affected by